AMG National Trust Bank Purchases 28 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AMG National Trust Bank boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 220 shares of the biopharmaceutical company’s stock after purchasing an additional 28 shares during the quarter. AMG National Trust Bank’s holdings in Regeneron Pharmaceuticals were worth $231,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. International Assets Investment Management LLC boosted its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares in the last quarter. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the first quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares in the last quarter. Swedbank AB acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $129,257,000. Finally, Epoch Investment Partners Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth $99,667,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Wolfe Research started coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective on the stock. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Barclays reduced their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Trading Down 2.3 %

Shares of Regeneron Pharmaceuticals stock opened at $744.60 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $736.19 and a 52-week high of $1,211.20. The stock has a market cap of $81.82 billion, a PE ratio of 18.43, a PEG ratio of 2.86 and a beta of 0.15. The firm has a 50-day moving average of $969.72 and a 200-day moving average of $1,032.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.